Drugs / marimastat
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00261391 | Oct 2000 → Oct 2007 | vascular malformation | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07500233 | Jan 2027 → Oct 2028 expected | snakebite envenomation | Liverpool School of Tropical Medicine | Not yet recruiting | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT00003010 | Dec 1997 → Dec 2004 | female breast carcinoma | Eastern Cooperative Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00002911 | Dec 1996 → May 2004 | lung cancer | ILEX Oncology Services, Incorporated | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00003011 Comparator | Jan 1997 → Feb 2001 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | marimastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003010 ↗ |
| Known as | BB 2516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL279785 ↗ |
| Known as | GI 5712 | ChEMBL registry synonym — accepted as the source's own label CHEMBL279785 ↗ |
| Known as | KB-R 8898 | ChEMBL registry synonym — accepted as the source's own label CHEMBL279785 ↗ |
| Known as | NSC-719333 | ChEMBL registry synonym — accepted as the source's own label CHEMBL279785 ↗ |
| Known as | TA 2516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL279785 ↗ |
| Action | Inhibit | “marimastat (a matrix metalloproteinase inhibitor)” NCT00002911 ↗6“Matrix metalloproteinase 12 inhibitor” CHEMBL279785 ↗ “Matrix metalloproteinase-2 inhibitor” CHEMBL279785 ↗ “Matrix metalloproteinase-1 inhibitor” CHEMBL279785 ↗ “Matrix metalloproteinase 9 inhibitor” CHEMBL279785 ↗ “Matrix metalloproteinase 7 inhibitor” CHEMBL279785 ↗ “Matrix metalloproteinase 3 inhibitor” CHEMBL279785 ↗ |
| Modality | Small molecule | — CHEMBL279785 ↗ |
| Route | Oral | “Patients are randomly assigned to receive either oral marimastat or oral placebo twice daily.” NCT00002911 ↗ |
| Target | MMP1 | “Matrix metalloproteinase-1 inhibitor” CHEMBL279785 ↗ |
| Target | MMP12 | “Matrix metalloproteinase 12 inhibitor” CHEMBL279785 ↗ |
| Target | MMP2 | “Matrix metalloproteinase-2 inhibitor” CHEMBL279785 ↗ |
| Target | MMP3 | “Matrix metalloproteinase 3 inhibitor” CHEMBL279785 ↗ |
| Target | MMP7 | “Matrix metalloproteinase 7 inhibitor” CHEMBL279785 ↗ |
| Target | MMP9 | “Matrix metalloproteinase 9 inhibitor” CHEMBL279785 ↗ |